miR-30b inhibits autophagy to alleviate hepatic ischemia-reperfusion injury via decreasing the Atg12-Atg5 conjugate

Figure 4 miR-30b alleviate AML12 cell ischemia-reperfusion injury by targeting Atg12 in vitro. A: The survival ratio of AML12 cells was measured after treatment with rapamycin or 3-MA; B: Western blot was used to detect the expression of LC3 and P62 in AML12 cells treated with Rapamycin or 3-MA; C: The survival ratio of AML12 cells was measured after treatment with miR-30b mimics or inhibitor; D: AML12 cells were transfected with Atg12 siRNAs, and the Atg12 mRNA and protein level of the target were evaluated using quantitative real time polymerase chain reaction or western blot analysis, respectively; E: The survival ratio of AML12 cells was measured at 12 h post-reperfusion in the absence or presence of miR-30b mimics, the miR-30b inhibitor, or Atg12 siRNA; F: Protein levels of Atg12 and LC3 were analyzed using western blot in AML12 cells at 12 h post-reperfusion in the absence or presence of miR-30b mimics, the miR-30b inhibitor, or Atg12 siRNA; ^aP < 0.05, ^bP < 0.01, ^cP < 0.001 vs IR/miR-NC group. Every experiment was repeated three times.